APTX - Aptinyx Inc.
| Previous Close | 4.6000 |
| Open | 5.0000 |
| Bid | 4.3600 x 1200 |
| Ask | 4.5900 x 3100 |
| Day's Range | 4.2100 - 5.1400 |
| 52 Week Range | 2.6100 - 6.0000 |
| Volume | 1,373,849 |
| Avg. Volume | 246,649 |
| Market Cap | 201.45M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7240 |
| Earnings Date | Mar 17, 2020 - Mar 22, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
- Benzinga
Notable Insider Buys Last Week: Small-Cap Biotechs
At two of them, the shares were sold in recent secondary offerings. Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. The following are a few of significant insider purchases reported last week, all small-cap biotechs.
- GuruFocus.com
Largest Insider Trades of the Week
Snap founder and CEO dumps 2.78 million shares Continue reading...
- GlobeNewswire
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the closing of its public offering of 11,691,666 shares of its common stock, which included the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of $3.00 per share. All of the shares sold in the offering were sold by Aptinyx. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Aptinyx, were approximately $35.1 million.
- GlobeNewswire
Aptinyx Announces Pricing of Public Offering of Common Stock
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the pricing of its public offering of 10,166,666 shares of its common stock at a public offering price of $3.00 per share. All of the shares sold in the offering will be sold by Aptinyx. In addition, Aptinyx has granted the underwriters a 30-day option to purchase up to 1,525,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
- Benzinga
The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...
- GlobeNewswire
Aptinyx Announces Proposed Public Offering of Common Stock
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Aptinyx also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares to be issued and sold in the public offering.
- Simply Wall St.
Did You Manage To Avoid Aptinyx's (NASDAQ:APTX) Devastating 80% Share Price Drop?
While it may not be enough for some shareholders, we think it is good to see the Aptinyx Inc. (NASDAQ:APTX) share...
- Insider Monkey
Is Aptinyx Inc. (APTX) A Good Stock To Buy?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- GlobeNewswire
Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference
EVANSTON, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference. Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
- GlobeNewswire
Aptinyx to Present Preclinical Data Exhibiting Effects of NYX-783 in Models of PTSD and Alcohol Use Disorder at the American College of Neuropsychopharmacology’s Annual Meeting
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced a presentation highlighting preclinical data on its novel NMDA receptor modulator, NYX-783. The studies were conducted in collaboration with the Medical University of South Carolina and Northwestern University. The presentation is taking place today, December 9, 2019, at the Annual Meeting of the American College of Neuropsychopharmacology in Orlando, Florida.
- GlobeNewswire
Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson’s Disease
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of a Phase 2 clinical study of its novel NMDA receptor modulator, NYX-458, for the treatment of mild cognitive impairment associated with Parkinson’s disease. The company expects to report top-line data from the 135-patient Phase 2 study in the second half of 2021.
- ACCESSWIRE
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 21, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. ...
- ACCESSWIRE
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 19, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. ...
- ACCESSWIRE
FIRST FIRM TO INVESTIGATE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 18, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc. ...
- ACCESSWIRE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX
NEW YORK, NY / ACCESSWIRE / November 15, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Aptinyx Inc. ("Aptinyx" or the "Company") (NASDAQ:APTX). Such investors ...
- GlobeNewswire
Aptinyx to Present at Upcoming Investor Conferences
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
- Zacks
Aptinyx Inc. (APTX) Reports Q3 Loss, Tops Revenue Estimates
Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 4.35% and 2.86%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Aptinyx Reports Third Quarter 2019 Financial Results and Highlights
Initiated two Phase 2 studies of NYX-2925 in chronic pain conditions On track to have four Phase 2 studies ongoing by year end across pipeline of CNS product candidates.
- GlobeNewswire
Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions
Aptinyx Inc. (APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of two Phase 2 studies evaluating NYX-2925 for the treatment of painful diabetic peripheral neuropathy (DPN) and for the treatment of fibromyalgia. NYX-2925 is a novel NMDA receptor modulator that has been granted Fast Track designation by the U.S. Food and Drug Administration.
- Simply Wall St.
How Much Of Aptinyx Inc. (NASDAQ:APTX) Do Insiders Own?
A look at the shareholders of Aptinyx Inc. (NASDAQ:APTX) can tell us which group is most powerful. Insiders often own...
- Zacks
Earnings Preview: Aptinyx Inc. (APTX) Q3 Earnings Expected to Decline
Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Aptinyx to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
EVANSTON, Ill., Nov. 05, 2019 -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and.
